Pro Medicus Expands US Footprint with AU$23 Million St. Luke’s Deal
Pro Medicus Limited (ASX: PME) has expanded its presence in the US healthcare imaging market after securing a seven-year agreement valued at AU$23 million with St. Luke’s Health System. The contract was awarded through its wholly owned subsidiary, Visage Imaging.
Under the agreement, St. Luke’s will adopt the cloud-based Visage 7 platform, incorporating Visage 7 Viewer and Visage 7 Workflow. The technology will create a unified imaging environment across the healthcare network, supporting more streamlined access to medical imaging services.
The agreement follows a transaction-based licensing structure, offering potential revenue upside as platform usage increases. Deployment preparations are commencing, with the system scheduled to go live during the first quarter of calendar year 2027.
The contract further strengthens Pro Medicus’ position in North America, while management indicated that its opportunity pipeline remains healthy across academic hospitals, integrated healthcare networks and private imaging organisations.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Pro Medicus Expands US Footprint with AU$23 Million St. Luke’s Deal
Pro Medicus Limited (ASX: PME) has expanded its presence in the US healthcare imaging market after securing a seven-year agreement valued at AU$23 million with St. Luke’s Health System. The contract was awarded through its wholly owned subsidiary, Visage Imaging.
Under the agreement, St. Luke’s will adopt the cloud-based Visage 7 platform, incorporating Visage 7 Viewer and Visage 7 Workflow. The technology will create a unified imaging environment across the healthcare network, supporting more streamlined access to medical imaging services.
The agreement follows a transaction-based licensing structure, offering potential revenue upside as platform usage increases. Deployment preparations are commencing, with the system scheduled to go live during the first quarter of calendar year 2027.
The contract further strengthens Pro Medicus’ position in North America, while management indicated that its opportunity pipeline remains healthy across academic hospitals, integrated healthcare networks and private imaging organisations.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au